https://sputniknews.in/20261122/12984540.html
Russian Scientists Develop Drug That Targets Antibiotic-Resistant Bacteria
Russian Scientists Develop Drug That Targets Antibiotic-Resistant Bacteria
Sputnik India
Specialists at the Gamaleya Research Center for Epidemiology and Microbiology have developed an agent against antibiotic-resistant strains of Klebsiella... 22.11.2026, Sputnik India
2026-11-22T19:32+0530
2026-11-22T19:32+0530
2026-11-22T19:32+0530
science & tech
health
european union (eu)
russia
science & tech
https://cdn1.img.sputniknews.in/img/07ea/0b/16/12984297_0:177:3073:1905_1920x0_80_0_0_2487510bc63269f8f2fcee943ec133c4.jpg
The development offers a way to counter resistance, since the danger comes not from the bacterium itself but from its strains that withstand standard treatment.
russia
Sputnik India
feedback.hindi@sputniknews.com
+74956456601
MIA „Rossiya Segodnya“
2026
Sputnik India
feedback.hindi@sputniknews.com
+74956456601
MIA „Rossiya Segodnya“
News
en_IN
Sputnik India
feedback.hindi@sputniknews.com
+74956456601
MIA „Rossiya Segodnya“
https://cdn1.img.sputniknews.in/img/07ea/0b/16/12984297_91:0:2822:2048_1920x0_80_0_0_c5ce044a155ceafa9902cd70f0a9b537.jpgSputnik India
feedback.hindi@sputniknews.com
+74956456601
MIA „Rossiya Segodnya“
health, european union (eu), russia, science & tech
health, european union (eu), russia, science & tech
Russian Scientists Develop Drug That Targets Antibiotic-Resistant Bacteria
Specialists at the Gamaleya Research Center for Epidemiology and Microbiology have developed an agent against antibiotic-resistant strains of Klebsiella pneumoniae.
The drug works differently from conventional antibiotics by blocking the bacteria's ability to produce toxins, move, invade cells, and form biofilms, rather than killing them outright.
Klebsiella pneumoniae can cause severe pneumonia, bloodstream infections, and urinary tract infections, with fatality rates reaching 40% to 70%.
In the EU, bloodstream infections caused by this bacterium rose 72% between 2019 and 2025, medical data shows.
The development offers a way to counter resistance, since the danger comes not from the bacterium itself but from its strains that withstand standard treatment.